Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097832 · ClinicalTrials.gov registry record · Phase 1
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
A Phase 1 study of Light Chain (AL) Amyloidosis, sponsored by Nexcella.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT06097832 is a Phase 1 study of Light Chain (AL) Amyloidosis that is actively recruiting participants, run by Nexcella. The registered enrollment target is 40 participants. The trial reports 18 study locations across 12 states.
The verdict
NCT06097832, a Phase 1 study of Light Chain (AL) Amyloidosis, is actively recruiting participants, sponsored by Nexcella.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Conditions Studied
Interventions
- BIOLOGICAL NXC-201 CAR-T
Study Locations (18)
California
- Sutter Health Alta Bates - Berkeley
- City of Hope - Duarte
- University of California Los Angeles - Los Angeles
- University of California Davis Medical Center - Sacramento
- Stanford University - Stanford
Massachusetts
- Tufts Medical Center - Boston
- Boston University Medical Center - Boston
Ohio
- University of Cincinnati Cancer Center - Cincinnati
- Cleveland Clinic - Cleveland
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Kansas
- The University of Kansas Cancer Center - Fairway
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Missouri
- Washington University Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2039-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06097832
The ClinicalTrials.gov registry entry for NCT06097832 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nexcella, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Light Chain (AL) Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which NXC-201 CAR-T is the first listed.
NCT06097832 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT06097832 about?
NCT06097832 is a clinical study titled "Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis". Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
What is the current status of trial NCT06097832?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-06-05. Estimated completion is 2039-01.
What conditions does trial NCT06097832 study?
This clinical trial studies the following conditions: Light Chain (AL) Amyloidosis.
What interventions are being tested in trial NCT06097832?
The interventions under investigation include: NXC-201 CAR-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT06097832?
This trial is sponsored by Nexcella, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097832 being conducted?
This trial has 18 study locations across California, Georgia, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.